Table:
Costs (USD)	Incremental effects	Incremental cost-effectiveness
80% MV wastage
Restrictive MV policy	54,420	0	Reference
MV-for-all policy	−1779	4223 discounted LYG	Cost-saving
MV-for-all policy	−1779	160 deaths averted	Cost-saving
70% MV wastage
Restrictive MV policy	54,420	0	Reference
MV-for-all policy	−28,406	4223 discounted LYG	Cost-saving
MV-for-all policy	−28,406	160 deaths averted	Cost-saving
33% reduction in mortality dueto MV as obtained from trial [11]
Restrictive MV policy	54,420	0	Reference
MV-for-all policy	78,102	3029 discounted LYG	7.8 USD/LYG
MV-for-all policy	78,102	115 deaths averted	206 USD/death averted
Lower confidence interval boundaryfrom WHO review (35%) [12]
Restrictive MV policy	54,420	0	Reference
MV-for-all policy	78,102	3212 discounted LYG	7.4 USD/LYG
MV-for-all policy	78,102	122 deaths averted	194 USD/death averted
Upper confidence interval boundaryfrom WHO review (55%) [12]
Restrictive MV policy	43,506	0	Reference
MV-for-all policy	78,102	5050 discounted LYG	4.7 USD/LYG
MV-for-all policy	78,102	192 deaths averted	124 USD/death averted
Using only costs incurred by the health system
Restrictive MV policy	25,497	0	Reference
MV-for-all policy	91,413	4223 discounted LYG	15.6 USD/LYG
MV-for-all policy	91,413	160 deaths averted	412 USD/death averted

Convert the table into Markdown language.

|  | Costs (USD) | Incremental effects | Incremental cost-effectiveness | 
 | --- | --- | --- | --- | 
 | 80% MV wastage |  |  |  | 
 | Restrictive MV policy | 54,420 | 0 | Reference | 
 | MV-for-all policy | −1779 | 4223 discounted LYG | Cost-saving | 
 | MV-for-all policy | −1779 | 160 deaths averted | Cost-saving | 
 | 70% MV wastage |  |  |  | 
 | Restrictive MV policy | 54,420 | 0 | Reference | 
 | MV-for-all policy | −28,406 | 4223 discounted LYG | Cost-saving | 
 | MV-for-all policy | −28,406 | 160 deaths averted | Cost-saving | 
 | 33% reduction in mortality dueto MV as obtained from trial [11] |  |  |  | 
 | Restrictive MV policy | 54,420 | 0 | Reference | 
 | MV-for-all policy | 78,102 | 3029 discounted LYG | 7.8 USD/LYG | 
 | MV-for-all policy | 78,102 | 115 deaths averted | 206 USD/death averted | 
 | Lower confidence interval boundaryfrom WHO review (35%) [12] |  |  |  | 
 | Restrictive MV policy | 54,420 | 0 | Reference | 
 | MV-for-all policy | 78,102 | 3212 discounted LYG | 7.4 USD/LYG | 
 | MV-for-all policy | 78,102 | 122 deaths averted | 194 USD/death averted | 
 | Upper confidence interval boundaryfrom WHO review (55%) [12] |  |  |  | 
 | Restrictive MV policy | 43,506 | 0 | Reference | 
 | MV-for-all policy | 78,102 | 5050 discounted LYG | 4.7 USD/LYG | 
 | MV-for-all policy | 78,102 | 192 deaths averted | 124 USD/death averted | 
 | Using only costs incurred by the health system |  |  |  | 
 | Restrictive MV policy | 25,497 | 0 | Reference | 
 | MV-for-all policy | 91,413 | 4223 discounted LYG | 15.6 USD/LYG | 
 | MV-for-all policy | 91,413 | 160 deaths averted | 412 USD/death averted |